Oncology
![PC-KR-103096-thumb2.png](/kr/sites/default/files/2023-09/PC-KR-103096-thumb2.png)
PDF
[GIOTRIF] In real-world practice, sequential afatinib followed by osimertinib is a feasible and effective therapeutic strategy for EGFR m+ NSCLC patients acquiring T790M during the period of afatinib treatment1
![PC-KR-096-thumb.png](/kr/sites/default/files/2023-09/PC-KR-096-thumb.png)
PDF
[GIOTRIF] Based on current real-world and clinical trial evidences, the optimal regimen maybe first-line afatinib followed by osimertinib4-
![over-1000.png](/kr/sites/default/files/2024-05/over-1000.png)
PDF
[GIOTRIF] Over 1000 published cases of patients with uncommon EGFR M+ NSCLC treated with GIOTRIF®
![PC-KR-103061-thumb.png](/kr/sites/default/files/2024-05/PC-KR-103061-thumb.png)
PDF